Taysha Gene Therapies (TSHA) director receives RSU and stock option grants

Rhea-AI Filing Summary

Taysha Gene Therapies director Laura Sepp-Lorenzino reported equity awards consisting of restricted stock units and stock options. She received 21,335 shares of Common Stock as a restricted stock unit (RSU) award, which will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to her continued service as a director. She was also granted a stock option for 42,671 shares of Common Stock at an exercise price of $5.97 per share, expiring on June 1, 2036. Following these awards, she directly holds 127,178 shares of Common Stock and 42,671 options.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Sepp-Lorenzino Laura

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	42,671	$0.00	--
Grant/Award	Common Stock	21,335	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 42,671 shares (Direct, null); Common Stock — 127,178 shares (Direct, null)

Footnotes (1)

1. Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Key Figures

RSU award: 21,335 shares Stock options granted: 42,671 options Option exercise price: $5.97 per share +3 more

6 metrics

RSU award 21,335 shares Restricted stock units vesting by June 1, 2027 or next annual meeting

Stock options granted 42,671 options Right to buy Common Stock granted to director

Option exercise price $5.97 per share Exercise price for 42,671-share stock option

Option expiration June 1, 2036 Expiration date of stock option grant

Common shares after award 127,178 shares Director’s direct Common Stock holdings following the RSU grant

Options held after grant 42,671 options Director’s stock option holdings following the grant

Key Terms

restricted stock unit ("RSU") award, Stock Option (right to buy), annual stockholders meeting, vesting date

4 terms

restricted stock unit ("RSU") award financial

"Represents a restricted stock unit ("RSU") award."

Stock Option (right to buy) financial

"Stock Option (right to buy) with an exercise price of $5.97."

annual stockholders meeting financial

"vest on the earlier of June 1, 2027 or the next annual stockholders meeting"

vesting date financial

"subject to the Reporting Person's continued service as a director through the applicable vesting date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sepp-Lorenzino Laura

(Last) (First) (Middle)

C/O TAYSHA GENE THERAPIES, INC.

3000 PEGASUS PARK DRIVE, SUITE 1430

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Taysha Gene Therapies, Inc. [ TSHA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		A		21,335(1)	A	$0	127,178	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.97	06/01/2026		A		42,671		(2)	06/01/2036	Common Stock	42,671	$0	42,671	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

2. The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

	/s/ Kamran Alam, Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did TSHA director Laura Sepp-Lorenzino report?

Laura Sepp-Lorenzino reported receiving equity awards from Taysha Gene Therapies, Inc., including restricted stock units and stock options. These are compensation-related grants rather than open-market purchases or sales, and they increase her overall equity stake in the company.

How many TSHA shares were granted as restricted stock units to the director?

She was granted 21,335 shares of Common Stock as a restricted stock unit (RSU) award. These RSUs represent share-based compensation and will convert into common shares if the vesting conditions related to her continued board service are satisfied.

What stock options did the TSHA director receive in this Form 4 filing?

She received a stock option covering 42,671 shares of Taysha Gene Therapies Common Stock with an exercise price of $5.97 per share. The option is a right to buy shares and expires on June 1, 2036, if not exercised earlier.

When do the TSHA director’s RSUs and option shares vest according to the filing?

Both the RSU award and the underlying shares for the stock option vest on the earlier of June 1, 2027 or the next annual stockholders meeting. Vesting is conditioned on her continued service as a director through the applicable vesting date.

What is Laura Sepp-Lorenzino’s TSHA share ownership after these transactions?

After the reported awards, she directly holds 127,178 shares of Taysha Gene Therapies Common Stock. In addition, she holds a stock option for 42,671 shares, giving her both current share ownership and a future right to purchase additional shares at a fixed price.

Were these TSHA insider transactions open-market buys or sells?

No, the transactions were classified as grants or awards, not open-market trades. The Form 4 uses transaction code A, indicating a grant or other acquisition as part of compensation, rather than a discretionary purchase or sale on the open market.